Last reviewed · How we verify
Tazemetostat and [14C] Tazemetostat
Tazemetostat and [14C] Tazemetostat is a Small molecule drug developed by Epizyme, Inc.. It is currently in Phase 1 development. Also known as: E7438, EPZ-6438.
At a glance
| Generic name | Tazemetostat and [14C] Tazemetostat |
|---|---|
| Also known as | E7438, EPZ-6438 |
| Sponsor | Epizyme, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tazemetostat and [14C] Tazemetostat CI brief — competitive landscape report
- Tazemetostat and [14C] Tazemetostat updates RSS · CI watch RSS
- Epizyme, Inc. portfolio CI
Frequently asked questions about Tazemetostat and [14C] Tazemetostat
What is Tazemetostat and [14C] Tazemetostat?
Tazemetostat and [14C] Tazemetostat is a Small molecule drug developed by Epizyme, Inc..
Who makes Tazemetostat and [14C] Tazemetostat?
Tazemetostat and [14C] Tazemetostat is developed by Epizyme, Inc. (see full Epizyme, Inc. pipeline at /company/epizyme-inc).
Is Tazemetostat and [14C] Tazemetostat also known as anything else?
Tazemetostat and [14C] Tazemetostat is also known as E7438, EPZ-6438.
What development phase is Tazemetostat and [14C] Tazemetostat in?
Tazemetostat and [14C] Tazemetostat is in Phase 1.
Related
- Manufacturer: Epizyme, Inc. — full pipeline
- Also known as: E7438, EPZ-6438
- Compare: Tazemetostat and [14C] Tazemetostat vs similar drugs
- Pricing: Tazemetostat and [14C] Tazemetostat cost, discount & access